Therapeutic proteins and peptides have emerged as one of the most important classes of new pharmaceuticals. Several drug candidates with potential performance-enhancing properties are currently in preclinical or clinical development. The current version of the WADA Prohibited List includes a variety of protein/peptide-based doping agents, some of which can be detected in biological samples by using immunological and mass spectrometry-based approaches.
Dr. Katja Walpurgis and Andreas Thomas of the Center for Preventive Doping Research of the German Sport University Cologne will present novel classes of protein-/peptide-based drugs such as Fc-fusion proteins and discuss strategies for their detection in doping control samples by means of the ACQUITY UPLC System and the SYNAPT G2S.
What will I learn?
- How novel protein-/peptide-based drugs such as Fc-fusion proteins and therapeutic antibodies can be detected in human matrices by using different proteomics techniques in combination with high resolution mass spectrometry.
- How ion mobility can help to identify prohibited substances in complex biological matrices.
Who should attend?
- Sports doping laboratories (human and animal doping)
- Forensic toxicology laboratories
- Drug testing laboratories
- Institutes of legal medicine
- Police forensic laboratories
- State crime laboratories
- People involved in toxicology research
- People interested in detecting novel protein/peptide therapeutics
